Video

Dr. Suresh Ramalingam on Frontline Osimertinib in EGFR+ NSCLC

Suresh Ramalingam, MD, professor of Hematology and Medical Oncology at Emory School of Medicine and deputy director of Winship Cancer Institute, discusses first-line treatment with single-agent osimertinib in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Suresh Ramalingam, MD, professor of Hematology and Medical Oncology at Emory School of Medicine and deputy director of Winship Cancer Institute, discusses first-line treatment with single-agent osimertinib in patients with EGFR-mutated non—small cell lung cancer (NSCLC).

As part of a phase I study, 60 patients with EGFR-mutated NSCLC received 80 or 160 mg of frontline osimertinib, which inhibits T790M mutation, a known driver of resistance to EGFR TKI. Updated efficacy data, reported at the ELCC meeting, demonstrated a response rate of around 76% in patients who received frontline osimertinib. The median duration of response has not yet been reached in the group receiving the 80 mg dose of osimertinib, as the majority of patients included in the study are still continuing to receive therapy, says Ramalingam. The median duration of response was 16.7 months in the patient group that receiving the 160 mg dose.

The median progression-free survival (PFS) was 19.3 months for patients receiving osimertinib at 160 mg once daily (n = 30) and was not yet reached for patients receiving the 80 mg dose (n = 30). This PFS is significant when compared to existing therapies for EGFR-mutated NSCLC, which have a the median PFS of around 9 to 13 months, says Ramalingam.

The regimen was well tolerated and most toxicities were grade I or II, he adds.

Osimertinib is currently approved by the FDA for patients with advanced EGFR T790M mutation—positive NSCLC who are resistant to EGFR TKI.

<<<

View more from the 2016 European Lung Cancer Conference

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS